# BlueSphere Bio

> BlueSphere Bio is a Pittsburgh-based clinical-stage biotechnology company developing personalized T-cell receptor (TCR) therapies for cancer. Spun out of the University of Pittsburgh and UPMC Enterprises in 2017, the company's proprietary TCXpress platform rapidly discovers and screens natural T-cell receptors that can target cancer antigens hidden inside cells - a reach beyond what conventional CAR-T therapies achieve. Its lead programs target high-risk hematologic malignancies such as relapsed/refractory acute myeloid leukemia.

- **Founded:** 2017
- **Headquarters:** Pittsburgh, Pennsylvania, United States
- **Founders:** Mark Shlomchik (Co-Founder & Scientific Founder (TCXpress technology)), Warren Shlomchik (Co-Founder, Professor of Medicine (Hematology-Oncology & Immunology)), Constantinos Panousis (Co-Founder)
- **Team size:** ~31 employees
- **Products:** TCXpress, NEOXpress, TCX-101, TCX-102
- **Notable:** First IND clearance from the FDA (June 2024) for a TCR therapy targeting high-risk leukemia., Strategic research collaboration with the National Cancer Institute., First standalone translational-sciences company spun out by UPMC Enterprises.

## Products & services

- **TCXpress** — Proprietary high-throughput platform that searches for, captures and functionally screens natural T-cell receptors capable of targeting cancer antigens - including intracellular targets - enabling in vitro screening before treatment.
- **NEOXpress** — Proprietary neoantigen discovery platform that identifies tumor-specific mutations and pairs them with TCRs, supporting a solid-tumor 'virtual patient' R&D program.
- **TCX-101** — Lead clinical TCR T-cell therapy program targeting high-risk hematologic malignancies such as relapsed/refractory acute myeloid leukemia.
- **TCX-102** — Clinical-stage TCR T-cell therapy program in the company's pipeline.

## Achievements

- First IND clearance from the FDA (June 2024) for a TCR therapy targeting high-risk leukemia.
- Strategic research collaboration with the National Cancer Institute.
- First standalone translational-sciences company spun out by UPMC Enterprises.
- Raised approximately $55.6 million in total funding across Series A and Series B.
- Built two proprietary discovery platforms, TCXpress and NEOXpress.

## Latest updates

- **2024-06** — FDA clears BlueSphere Bio's first IND for a TCR therapy targeting relapsed/refractory AML and other high-risk hematologic malignancies.
- **2024-06** — Announced research collaboration with the National Cancer Institute on a rare-disease TCR program.
- **2025-07** — Featured by BioBuzz as advancing next-level personalized cancer cell therapy; Phase 1 trial expected to complete in early 2026 with a pivotal trial planned for 2027.

## Links

- Website: https://bluespherebio.com
- LinkedIn: http://www.linkedin.com/company/bluesphere-bio
- Twitter/X: https://twitter.com/BluesphereBio

---

Profile page: https://yespress.io/bluesphere-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-07